A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

Phase 2 Recruiting 60 enrolled Ausper Biopharma Co., Ltd.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is an open-label, multicenter phase II clinical study to evaluate the efficacy and safety of AHB-137 injection in participants with CHB previously treated with NA.

Timeline

Start: 2025-09-04
Primary completion: 2026-12-12
Completion: 2027-06-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AHB-137	Antisense oligonucleotide	—	Other

A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

Summary

Timeline

Drugs

Indications